New drugs drive optimism at AstraZeneca

Reported half-year numbers from pharma giant AstraZeneca (AZN) were poor. Drug sales fell 2 per cent to $10bn (£7.6bn) at constant currencies, while rising costs sent core operating profits down 34 per cent to $2.2bn.